InClin, Inc.   Report issue

For profit Phase 2
Founded: San Mateo CA United States (1998)

Organization Overview

First Clinical Trial
2018
NCT03560271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

InClin | InClin, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

cyclo-His-Pro (1 trial)

endoxifen (1 trial)

exemestane (aromasin) (1 trial)

goserelin (zoladex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4